EQT IX, a buyout group, is set to acquire Recipharm, a pharmaceutical contract development and manufacturing organization, for $2.97bn. The shareholders of Recipharm are offered $27.8 in cash per class B share in Recipharm. "Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market. EQT wants to support Recipharm's continued development, which will require significant and long-term investments. We value Recipharm's management team and employees highly, and look forward to partnering with Lars Backsell and Thomas Eldered. We share many of the founders' values, including the importance of an entrepreneurial approach and a clear sustainability focus. As a very active investor in the global healthcare sector, EQT is well positioned to support Recipharm to futureproof its operations and accelerate its growth. We are convinced that we can add significant value, both in terms of expertise and capital," Erika Henriksson, EQT Partners Partner. On January 28, 2021, EQT raised its bid to $27.8 per share from the $26.4 offer, valuing Recipharm at $2.97bn.